Asthma Research Results
A Survey and Questionnaire by Dr.
Nyjon K. Eccles BSc MBBS PhD MRCP, The Chiron Clinic, 121
Harley Street & Jerry Yamoa, NHC Ltd.
- 200 Questionaires sent out. 120 Returned.
60% Response.
- Number of Asthma patients: 70
- Mean duration of Asthma: 16.4 years
- Age Range: 1 - 68 years
- Male patients: 49%; Female patients: 41%;
Gender unknown: 10%
- 14 patients aged 1 - 29yrs; 40 patients aged
30 - 59yrs; 15 patients aged 60 - 89yrs
44% of patients who took part in the survey
were Caucasian. 25% were African; 12% were Asian; 10% were
Afro-Carribean and 9% were of undisclosed origin.
The reported number of attacks in one year experienced by the group
before taking Yamoa was 78. Attacks dropped to 22 per year after
Yamoa.
On average patients took some form of asthma medication 3.6 times a
day before taking Yamoa Powder. The average number of times medication
has been required on a daily basis since Yamoa has been taken is 1.7
times a day.
There were 3 hospital admissions amongst the group who responded to
the survey before Yamoa was taken. Afterwards, there were none before
the survey was completed.

The reported number of attacks in one year experienced by the group
before taking Yamoa was 78. Attacks dropped to 22 per year after
Yamoa.
On average patients took some form of asthma medication 3.6 times a
day before taking Yamoa Powder. The average number of times medication
has been required on a daily basis since Yamoa has been taken is 1.7
times a day.
There were 3 hospital admissions amongst the group who responded to the
survey before Yamoa was taken. Afterwards, there were none before the
survey was completed.
The average peak flow rate reading taken before Yamoa was 350. The
average taken since using Yamoa Powder was 420. This means an average
improvement of 70.
12% of patients found no benefits from taking Yamoa. 19% experienced
a mild improvemnt in their condition. 29% reported a CURE. 40%
reported a marked improvement in their condition.
Thus 69%, that is 69 people in every 100, experienced AT LEAST a
marked improvement in their asthma as a result of taking Yamoa
Powder.
Indications show that greater benefits may be achieved the younger the
patient. This may be because the condition has not been with younger
patients as long as for those in the older group; they may not have
the history of stress and illness that older people have, in which
case younger immune systems may be stronger than old. The younger
group most likely does not have other contributing factors such as
life-long smoking history etc.